14 results about "Fibroma" patented technology

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.

In one embodiment, the present application discloses, in part, biologically active compositions comprising a Crila® composition, or an admixture of Crinum latifolium L. dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the Crinum latifolium L. dry extract to EGCG, and their use in the treatment of intramural or subserosal fibroids and various related diseases.

The application discloses application of FTY720 as a PP2A phosphatase activator in preparation of a medicine for treating type I neurofibromatosis. The application first uses FTY720 for treatment of type I neurofibromatosis, and proves that FTY720 significantly inhibits formation of neurofibromas by non-specifically activating PP2A phosphatase. In-vivo experimental results show that FTY720 as a single drug can significantly inhibit tumor growth, and a synergistic effect is presented when FTY720 is combined with a MEK inhibitor, and tumor growth is almost completely inhibited. In-vitro cell experiments show that FTY720 as a single drug or in combination with MEKi treatment can inhibit tumor Schwann cells from forming tumor spheres, inhibit cell proliferation and migration, and induce tumor cell apoptosis. The application overcomes the drug resistance problem existing in the prior art MEK inhibitor, and provides a new treatment strategy for type I neurofibromatosis. FTY720 is an FDA-approved drug, and has good safety and drugability, and has high clinical conversion potential.

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects. Where the methods of treatment include intralesionally injecting a pharmaceutical formulation comprising collagenase into one or more plantar fibromatosis nodules in one or both of the subject's feet or the population of subjects' feet to thereby treat the plantar fibromatosis. The collagenase has enzymatic activity in regards to collagen. The treatment may result in a change from a baseline or control of a scale to determine effectiveness.

This application relates, in certain embodiments, to a method and composition for treating soft tissue sarcomas (STS, e.g., spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma) using a composition comprising nanoparticles containing an mTOR inhibitor (e.g., limus drugs, e.g., sirolimus or its derivatives) and albumin in combination with a multityrosine kinase inhibitor (e.g., pazopanib).

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

In one embodiment, the present application discloses, in part, biologically active compositions comprising a Crila® composition, or an admixture of Crinum latifolium L. dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the Crinum latifolium L. dry extract to EGCG, and their use in the treatment of intramural or subserosal fibroids and various related diseases.

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

Provided are novel collagen 1 translational inhibitors, compositions comprising the same, methods of making the same, and uses thereof for treating fibrosis (including pulmonary fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, skin fibrosis), IPF (idiopathic pulmonary fibrosis), wound-healing, scar fibromatosis, gingival fibromatosis, systemic sclerosis, alcoholic fat hepatitis, and non-alcoholic fat hepatitis (NASH).SOLUTION: A compound of Formula V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, isotopic variant, reverse amide analog, or any combination thereof is provided. Wherein X1, X2, X4, and X5 are each independently C or N; X3 is N.SELECTED DRAWING: Figure 1

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.

The application discloses siRNA for inhibiting expression of a CREPT gene, wherein a positive sense chain nucleotide sequence of the siRNA is shown in any one of SEQ ID No. 1-3. The siRNA can inhibit the CREPT. Some siRNAs can inhibit growth of mouse colon cancer cells and growth of NIH3T3 fibrosarcoma cells. The liposome delivery drug of the si-CREPT through a delivery system can treat mouse liver cancer, and significantly reduce tumor load of the mouse liver cancer.

The invention belongs to the field of drug delivery, and relates to a liposome preparation, in particular to pegylated liposome adriamycin and application thereof in treating advanced and refractory invasive fibroma. The pegylated liposome doxorubicin comprises doxorubicin hydrochloride, polyethylene glycol-lipid, cholesterol and phospholipid. The pegylated liposome doxorubicin liposome disclosed by the invention is small in particle size, high in encapsulation efficiency and high in stability, and has a remarkable curative effect on advanced and refractory invasive fibroma.